Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
KRAS and conjugates remain hot
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.
